Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK cells + amniotic epithelial cells
- Development stage
- Unknown
- Lead developer
- The Second Affiliated Hospital of Fujian Medical University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
This investigational combination cellular immunotherapy consists of intravenous natural killer (NK) cells and intrathecal amniotic epithelial cells. Developed by The Second Affiliated Hospital of Fujian Medical University in collaboration with Shanghai iCELL Biotechnology, the therapy is being evaluated for the treatment of HTLV-1 associated myelopathy (HAM), a chronic progressive spinal cord disease caused by human T-lymphotropic virus type 1. The treatment strategy utilizes the innate anti-viral activity of NK cells to target and eliminate HTLV-1 infected cells, while the amniotic epithelial cells are intended to provide immunomodulatory and potentially neuroprotective effects within the spinal cord environment to mitigate the associated inflammatory response.
- Other names
- NK cells-The Second Affiliated Hospital of Fujian Medical University-HTLV-1 associated myelopathyNK cells and amniotic epithelial cellsImmunotherapy of Natural Killer in HTLV-1 Associated Myelopathy
Beyond the preview
Go deeper on NK cells + amniotic epithelial cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK cells + amniotic epithelial cells.